-+ 0.00%
-+ 0.00%
-+ 0.00%

Citizens Maintains Market Outperform on Kalaris Therapeutics, Lowers Price Target to $25

Benzinga·05/13/2026 14:24:20
Listen to the news
Citizens analyst Jonathan Wolleben maintains Kalaris Therapeutics (NASDAQ:KLRS) with a Market Outperform and lowers the price target from $26 to $25.